Durvalumab (durva) plus carboplatin/paclitaxel (CP) followed by maintenance (mtx) durva ± olaparib (ola) as a first-line (1L) treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): Results from the phase III DUO-E/GOG-3041/ENGOT-EN10 trial

被引：5

作者：

Westin, S. N. ^{[1
]}

Moore, K. N. ^{[2
]}

Chon, H. S. ^{[3
]}

Lee, J. Y. ^{[4
]}

Pepin, J. Thomes ^{[5
]}

Sundborg, M. ^{[6
]}

De la Garza, J. ^{[7
]}

Nishio, S. ^{[8
]}

Wang, K. ^{[9
]}

Mcintyre, K. ^{[10
]}

Tillmanns, T. ^{[11
]}

Mejia, F. Contreras ^{[12
]}

De Melo, A. C. ^{[13
]}

Klasa-Mazurkiewicz, D. ^{[14
,15
]}

Papadimitriou, C. A. ^{[16
,17
]}

Martin, M. Gil ^{[18
,19
]}

Brasiuniene, B. ^{[20
,21
]}

Donnelly, C. ^{[22
]}

Liu, X. ^{[23
]}

Van Nieuwenhuysen, E. ^{[24
,25
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr Houston, Div Surg, Dept Gynecol Oncol & Reprod Med, Houston, TX USA

[2] Univ Oklahoma, Dept Obstet & Gynecol, Stephenson Canc Ctr, Med Ctr, Oklahoma City, OK USA

[3] Univ S Florida, Moffitt Canc Ctr, Tampa, FL USA

[4] Yonsei Univ, Dept Obstet & Gynecol, Coll Med, Seoul, South Korea

[5] Minnesota Oncol, Dept Gynecol Oncol, Maplewood, MN 5 USA

[6] First Health Moore Reg Hosp, Dept Obstet & Gynecol, Pinehurst, NC USA

[7] Texas Oncol San Antonio Med Ctr, Dept Gynecol Oncol, San Antonio, TX USA

[8] Kurume Univ, Dept Obstet & Gynecol, Sch Med, Kurume, Fukuoka, Japan

[9] Med Univ Canc Inst Hosp, Dept Gynecol Oncol, Tianjin, Peoples R China

[10] Texas Hlth Presbyterian Hosp, Dept Med Oncol, Dallas, TX USA

[11] West Canc Ctr & Res Inst, Div Gynecol Oncol, Germantown, TN USA

[12] Natl Canc Inst Colombia, Clin Oncol, Bogota, Colombia

[13] Brazilian Natl Canc Inst, Clin Res & Technol Dev Div, Rio De Janeiro, Brazil

[14] Med Univ Gdansk, Dept Obstet & Gynecol, Gynecol Oncol & Gynecol Endocrinol, Gdansk, Poland

[15] PGOG, Gdansk, Poland

[16] Natl & Kapodistrian Univ Athens, Nd Dept Surg Aretaie Hosp, Athens, Greece

[17] HeCOG, Athens, Greece

[18] Hosp Duran & Reynals, Catalan Inst Oncol Inst Invest Biomed Bell, Med Oncol Dept, Lhospitalet Barcelona, Spain

[19] GEICO, Barcelona, Spain

[20] Natl Canc Inst Lithuania, Fac Med Vilnius Univ, Dept Med Oncol, Vilnius, Lithuania

[21] NSGO, Vilnius, Lithuania

[22] AstraZeneca, Oncol Biometr, Cambridge, England

[23] AstraZeneca, Oncol R&D, Latestage Dev, Gaithersburg, MD USA

[24] UZ Leuven, Dept Oncol, Leuven, Belgium

[25] BGOG, Leuven, Belgium

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.035

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA41

引用

页码：S1282 / S1283

页数：2

共 12 条

[1] DUO-E/GOG-3041/ENGOT-EN10: a randomized phase III trial of first-line carboplatin (carb) and paclitaxel (pac) in combination with durvalumab (durva), followed by maintenance durva with or without olaparib (ola), in patients (pts) with newly diagnosed (nd) advanced or recurrent endometrial cancer (EC).
Westin, Shannon Neville
Moore, Kathleen N.
Van Nieuwenhuysen, Els
Oza, Amit M.
Mileshkin, Linda R.
Okamoto, Aikou
Suzuki, Akiko
Meyer, Kassondra
Barker, Laura
Rhee, Joon
Vergote, Ignace
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[2] Durvalumab plus carboplatin/paclitaxel followed by durvalumab ± olaparib as a first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: results from the phase III DUO-E/GOG-3041/ENGOT-EN10 Trial
Westin, Shannon N.
Moore, Kathleen N.
Chon, Hye Sook
Lee, Jung-Yun
Pepin, Jessica Thomes
Sundborg, Michael
Garza, Joseph De La
Nishio, Shin
Wang, Ke
Mcintyre, Kristi
Tillmanns, Todd D.
Mejia, Fernando Contreras
Melo, Andreia Cristina De
Klasa-Mazurkewicz, Dagmara
Papadimitriou, Christos
Gil-Martin, Marta
Brasiuniene, Birute
Donnelly, Conor
Liu, Xiaochun
Nieuwenhuysen, Els Van
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A24 - A25
[3] Safety and tolerability of durvalumab plus carboplatin/paclitaxel followed by durvalumab ± olaparib in patients with newly diagnosed advanced or recurrent endometrial cancer (EC) in the DUO-E/GOG-3041/ENGOT-EN10 trial.
Pepin, Jessica Thomes
Chon, Hye Sook
Sundborg, Michael J.
Gold, Michael A.
Kim, Byoung-Gie
Blank, Stephanie V.
Liu, Ji-Hong
McCollum, Michael
Mori, Masahiko
Moore, Kathleen N.
Diaz, Julian Rivera
de Padua, Charles Andree Joseph
Martinez-Garcia, Jeronimo
Papadimitriou, Christos
Grian, Karin
Poka, Robert
Kowgier, Matthew
Oscroft, Emma
Van Nieuwenhuysen, Els
Westin, Shannon Neville
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[4] Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial
Westin, Shannon N.
Moore, Kathleen
Chon, Hye Sook
Lee, Jung-Yun
Pepin, Jessica Thomes
Sundborg, Michael
Shai, Ayelet
de la Garza, Joseph
Nishio, Shin
Gold, Michael A.
Wang, Ke
Mcintyre, Kristi
Tillmanns, Todd D.
Blank, Stephanie V.
Liu, Ji-Hong
Mccollum, Michael
Mejia, Fernando Contreras
Nishikawa, Tadaaki
Pennington, Kathryn
Novak, Zoltan
De Melo, Andreia Cristina
Sehouli, Jalid
Klasa-Mazurkiewicz, Dagmara
Papadimitriou, Christos
Gil-Martin, Marta
Brasiuniene, Birute
Donnelly, Conor
del Rosario, Paula Michelle
Liu, Xiaochun
Van Nieuwenhuysen, Els
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (03) : 283 - 299
[5] Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as a firstline treatment for endometrial cancer: Overall survival and additional secondary efficacy en-dpoints by mismatch repair status in the DUO-E/GOG-3041/ ENGOT-EN10 Trial
Baurain, Jean-Francois
Chon, Hye Sook
Pepin, Jessica Thomes
Sundborg, Michael
Gold, Michael
Kim, Byoung-Gie
Blank, Stephanie
Liu, Ji-Hong
McCollum, Michael
Mori, Masahiko
Jonuskiene, Goda
Moore, Kathleen
Novak, Zoltan
Ramos Guette, Pedro Luis
Joseph de Padua, Charles Andree
Martin, Marta Gil
Kowgier, Matthew
del Rosario, Paula Michelle
Westin, Shannon
Van Nieuwenhuysen, Els
GYNECOLOGIC ONCOLOGY, 2024, 190 : S62 - S63
[6] Durvalumab plus carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer (EC) in DUO-E: Results by BRCA1/BRCA2 mutation (BRCAm) status
Van Nieuwenhuysen, Els
Baurain, Jean-Francois
Chon, Hye Sook
Pepin, Jessica Thomes
Sundborg, Michael J.
Gold, Michael A.
Kim, Byoung-Gie
Blank, Stephanie V.
Liu, Ji-Hong
McCollum, Michael
Mori, Masahiko
Jonuskiene, Goda
Moore, Kathleen N.
Novak, Zoltan
Ramos, Pedro
Andree, Charles
de Padua, Joseph
Gil-Martin, Marta
Kowgier, Matthew
del Rosario, Paula Michelle
Westin, Shannon Neville
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[7] Durvalumab plus carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as a first-line treatment for endometrial cancer (EC): Progression-free survival (PFS) by clinical factors in DUO-E
Blank, S. V.
McCollum, M.
Anderson, C.
Pennington, K.
Salinas, E.
Richardson, D. L.
Slomovitz, B. M.
Kim, B-G.
Liu, J.
Mori, M.
Guette, P. L. Ramos
de Padua, C. Joseph
Martinez-Garcia, J.
Papadimitriou, C.
Grisan, K.
Poka, R. L.
Kowgier, M.
Del Rosario, P. M. D.
Van Nieuwenhuysen, E.
Westin, S.
ANNALS OF ONCOLOGY, 2024, 35 : S557 - S557
[8] Erratum: Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial (Oct,10.1200/JCO.23.02132,2023)
Westin, Shannon N.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (27) : 3262 - 3262
[9] Durvalumab plus paclitaxel/carboplatin plus bevacizumab followed by durvalumab, bevacizumab plus olaparib maintenance among patients with newly-diagnosed advanced ovarian cancer without a tumor BRCA1/BRCA2 mutation: Updated results from DUO-O/ENGOT-OV46/GOG-3025 Trial
Harter, Philipp
Wimberger, Pauline
Okamoto, Aikou
Reuss, Alexander
Lim, Myong Cheol
Rubio-Perez, Maria Jesus
Vardar, Mehmet Ali
Scambia, Giovanni
Tredan, Olivier
Hietanen, Sakari
Colombo, Nicoletta
Chudecka-Glaz, Anita
Petru, Edgar
Lheureux, Stephanie
Van Nieuwenhuysen, Els
Sehouli, Jalid
Wenham, Robert
Ushijima, Kimio
Indiviglio, Sandra
Aghajanian, Carol
GYNECOLOGIC ONCOLOGY, 2024, 190 : S65 - S66
[10] DURVALUMAB WITH PACLITAXEL/CARBOPLATIN plus BEVACIZUMAB THEN MAINTENANCE DURVALUMAB, BEVACIZUMAB plus OLAPARIB IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER WITHOUT A TUMOUR BRCA1/2 MUTATION: RESULTS FROM THE DUO-O/ENGOT-OV46/AGO-OVAR 23/GOG-3025 TRIAL
Marth, Christian
Park-Simon, Tjoung-Won
Aghajanian, Carol
Reuss, Alexander
Nishio, Shin
Lim, Myong Cheol
Rubio-Perez, Maria Jesus
Vardar, Mehmet Ali
Scambia, Giovanni
Sabatier, Renaud
Haslund, Charlotte
Colombo, Nicoletta
Chudecka-Glaz, Anita
Lheureux, Stephanie
Huygh, Greet
Schochter, Fabienne
Wenham, Robert M.
Okamoto, Aikou
Day, Emily
Harter, Philipp
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A428 - A429

← 1 2 →